As the industry recovers, biotech stocks like Humanigen, Inc. (NASDAQ: HGEN), Oramed Pharmaceuticals (NASDAQ: ORMP) and MyMD Pharmaceuticals, Inc. (NASDAQ: MYMD) are quickly garnering much-deserved attention from investors. In this article, we dive into all the reasons why we’re watching these stocks in the coming days as well as their upcoming catalysts. Stay up to date with the BEST and CHEAPEST biotech stocks to buy here!
Promising Biotech stocks #1: HGEN
Humanigen, Inc. (NASDAQ: HGEN) – a late-stage clinical biopharma company – is most known for its work to prevent & treat a life-threatening systemic immune hyper-response, associated with COVID-19, called: cytokine storm. For years now, the company has worked on developing Lenzilumab – a proprietary Humaneered first-in-class monoclonal antibody that neutralizes GM-CSF – a cytokine of critical importance in the hyperinflammatory cascade – cytokine storm.
On July 7th, the company announced a peer-reviewed publication in Thorax– one of the world’s leading respiratory medicine journals and the official journal of the British Thoracic Society. The report supported Early Treatment of Hospitalized COVID-19 Patients with Lenzilumab Guided by C-Reactive Proteinsaw and highlighted a 62% reduction in the relative risk of progression to mechanical ventilation or death.
Commenting on that, Dale Chappell, M.D. – HGEN’s Chief Scientific Officer – said that: “these data demonstrate the importance of selecting the right treatment for the right patient at the right time”. As of now, 90% of LIVE-AIR patients treated with Lenzilumab in addition to standard of care are more likely to survive without mechanical ventilation – compared to only 79% treated with placebo and standard of care.
Dr. Cameron Durrant – Chairman & CEO – is bullish on this progress saying:
We believe data from our LIVE-AIR study provides a compelling argument for utilizing CRP as a biomarker to identify hospitalized patients for whom lenzilumab may provide the greatest benefit and we look forward to results of the NIH’s ACTIV-5/BET-B study of lenzilumab, which is designed to confirm this approach”.
Following its run-up, HGEN is now trading at $3 with a new resistance at 3.2 along with support at 2.09 and 1.84. Accumulation has been fluctuating but is recently seeing an uptick, meanwhile, the MACD is bullish but seems poised for another crossover soon. On a similar trend, the RSI is at 76 – indicating the stock is currently overbought.
As more results resurface, HGEN could see another run-up to break its resistance sooner than expected. However, given that the stock is currently overbought, it is likely that HGEN could retest its support before seeing an increase again. For this reason, bullish investors could wait for a pullback before securing a position on one of the most promising biotech stocks this week.
Promising Biotech stocks #2: ORMP
In its recent shareholder letter, clinical-stage biotech Oramed Pharmaceuticals (NASDAQ: ORMP) announced several updates regarding the company and its subsidiary; Oravax Medical. Most importantly, the company reported a solid financial stance and robust balance sheet with $169 million in cash and investments.
With this in mind, the company is well-positioned financially and clinically and has multiple important milestones expected to play out in the upcoming quarters. As a matter of fact, CEO Nadav Kidron believes that:
This position gives us sufficient runway to complete our pivotal oral insulin (ORMD-0801) Phase 3 trials and advance us towards potential FDA approval.”
Speaking of which, the shareholder letter also mentioned that as of Q1 2023, the company plans to achieve one of its most significant milestones. Under a U.S. FDA protocol, ORMP plans to report top-line efficacy data in the world’s first-ever pivotal Phase 3 oral insulin trial for the treatment of type 2 diabetes. As of now, the compnay has already enrolled 710 participants – greatly surpassing the number of planned participants in the first of its two oral insulin trials ORA-D-013-1.
The release of this oral type 2 diabetes therapy could be an extremely lucrative opportunity for ORMP. Investors are quickly realizing the untapped potential of this company. This is evident as ORMP has seen a huge uptick in volume – with over 14.5 million shares being traded at the time of this writing. This run-up is likely to continue as more of its catalysts play out over the next six months.
Closing the trading week on a high note, ORMP is now trading at $8.21 near its resistance of 8.22. With support at 4.45 and 4.16, it seems investors are quickly realizing the untapped potential of this company. Accumulation has been climbing steadily and despite its slight downfall, it has recently seen an uptick. Similarly, the MACD is bullish to the upside with no signs of an incoming crossover and the RSI is at 80 – indicating ORMP is extremely overbought at the moment.
If the company announces FDA- approval of its drugs, ORMP could be set for another run-up soon to break its resistance – making now a good entry point for bullish biotech investors. However, given that the stock is currently overbought, it is likely for it to calm down before heading on another run. This is why investors could secure a starter position now and average up on their investment from there.
Promising Biotech stocks #3: MYMD
As a clinical-stage pharmaceutical company, MyMD Pharmaceuticals, Inc. (NASDAQ: MYMD) has been focused on developing 2 novel therapeutic platforms that treat causes of disease instead of only addressing symptoms. The company is most known for its commitment to extending a healthy lifespan.
The company’s first platform – MYMD-1 – is a drug platform being developed to delay aging, increase longevity, and treat autoimmune diseases. Meanwhile, its second drug platform – Supera-CBD – is being developed to treat chronic pain, addiction, and epilepsy.
Commenting on the progress, Chris Chapman, M.D. – President, Director, and Chief Medical Officer- said:
With all trial sites now enrolling patients, we expect the pace of enrollment to speed up over the next several months. As we continue to advance our trial, we currently expect efficacy data in the second half of 2022. This trial remains our number one priority in our product development strategy.”
Given that MYMD has not identified any other FDA-approved drugs for treating aging disorders and extending the healthy lifespan of humans – a market that’s expected to be valued at around $600 billion by 2025 – the company could be set to gain immensely if it dominates this extremely lucrative sector.
Let’s take a look at where the stock’s at now….
Following its recent run-up, MYMD is currently trading at $4.23 with support at 2.2 and 2.09. Accumulation has been on an uptrend but is recently fluctuating and could drop in the coming days as investors cash out for-profits after the massive increase in the PPS. Meanwhile, the MACD is bullish with no signs of an incoming crossover and the RSI is holding at 80 – indicating MYMD is currently overbought and affirming investors’ bullish sentiment.
BOTTOM LINE
With the industry rebounding from a rough nine-month period, biotech stocks have been a hot topic these past few weeks. This is why aggressive investors are increasingly on the lookout for the best biotechs to invest in. Get alerts on the best entry points for promising biotech stocks and make major returns INSTANTLY!
As always, good luck to all (except the shorts)!
WHEN VIRAL STOCKS HAS A STOCK ALERT, IT CAN PAY TO LISTEN. AFTER ALL, OUR FREE NEWSLETTER HAS FOUND MANY TRIPLE-DIGIT WINNERS FOR OUR SUBSCRIBERS. WE SPECIALIZE IN FINDING MOMENTUM BEFORE IT HAPPENS!
Disclosure: We have no business relationship with any company whose stock is mentioned in this video. Viral Stocks is not an investment advisor and this video does not provide investment advice. Always do your own research, make your own investment decisions, or consult with your nearest financial advisor. This video is not a solicitation or recommendation to buy, sell, or hold securities. This video is our opinion and is meant for informational and educational purposes only and does not provide investment advice. Past performance is not indicative of future performance.
